Zymeworks Inc. (ZYME)
NASDAQ · Manufacturing · Pharmaceutical preparations
ZYME price, last 12 months
Key stats
- Previous close
- $26.04
- Open
- $25.99
- Day range
- $25.50 – $27.46
- 52-week range
- $21.52 – $31.97
- Volume
- 1M
- Avg volume (20 days)
- 1.2M
- Market cap
- $1.8B
Performance
Technicals and fundamentals
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.8B